We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Hologic's Genius AI Detection Shows Value by Spotting Missed Cancers
Read MoreHide Full Article
Key Takeaways
Hologic's Genius AI Detection flagged roughly 32% of false-negative mammograms in the 7,500-exam study.
HOLX's AI technology correctly spotted the location of breast cancer in one-third of initially missed cases.
Hologic's AI tool demonstrated similar accuracy to radiologists reviewing difficult breast cancer cases.
Hologic’s (HOLX - Free Report) AI-powered mammography solutions are gaining clinical momentum. Amid ongoing radiologist shortages, the company’s 3DQuorum technology has shown potential to streamline radiologists’ workflows and save time while maintaining high effectiveness in detecting cancers. The Genius AI Detection solution, designed to locate lesions likely to represent breast cancer, was found to perform on par with radiologists reviewing challenging breast cancer cases. Recently, Hologic announced new data from a retrospective analysis highlighting how the technology can help detect more breast cancers. The study was published in the American Journal of Roentgenology.
Between 2016 and 2019, researchers at a top-tier medical facility conducted 7,500 digital breast tomosynthesis (3D mammography) screening exams using the Genius AI Detection solution. There were 100 false-negative cases, which mammograms read as negative but were followed by a breast cancer diagnosis within the next year.
The Genius AI Detection solution marked approximately one-third (32%) of these cases, including areas of suspicion, accurately identifying the location where breast cancer was subsequently diagnosed.
Among the 500 breast cancer cases previously identified by radiologists, the Genius AI Detection technology flagged almost 90% and correctly localized their locations. The AI technology was more likely to flag invasive ductal carcinomas and lymph node-positive cancers in the study. It was less likely to flag invasive lobular carcinomas and grade I invasive carcinomas.
However, the study had limitations. Conducted at a single academic medical center with a predominantly Caucasian patient population using the Genius AI Detection 2.0 software, results may not extend to other practice settings or AI-based algorithms. The small sample sizes within certain subgroup also limit the statistical power and generalizability of the subgroup analyses.
Updates From HOLX Peers: GEHC and BDX
GE Healthcare (GEHC - Free Report) announced that it would supply more than 300 CT (computed tomography) scanners under Indonesia’s Strengthening Indonesia’s Health Referral Network (SIHREN) program to deliver equitable, high-quality care to more than 280 million Indonesians. As part of a competitively awarded, multi-year contract, the company will supply the advanced CT scanners to public hospitals across all 38 provinces, including urban and remote areas.
Becton, Dickinson and Company (BDX - Free Report) announced the expansion of its respiratory and sexually transmitted infection (STI) diagnostics offerings in Europe, with In Vitro Diagnostic Medical Device Regulation-certified VIASURE assays. BDX developed these assays in partnership with Certest Biotec for use on the BD MAX System.
HOLX Stock Performance, Valuation and Estimates
In the past three months, Hologic shares have risen 10% compared with the industry’s 8.6% growth.
Image Source: Zacks Investment Research
Hologic is trading at a forward five-year price-to-sales (P/S) of 3.86X, lower than the industry average of 4.36X.
Image Source: Zacks Investment Research
See how analysts are projecting Hologic’s fiscal 2026 and 2027 earnings.
Image: Bigstock
Hologic's Genius AI Detection Shows Value by Spotting Missed Cancers
Key Takeaways
Hologic’s (HOLX - Free Report) AI-powered mammography solutions are gaining clinical momentum. Amid ongoing radiologist shortages, the company’s 3DQuorum technology has shown potential to streamline radiologists’ workflows and save time while maintaining high effectiveness in detecting cancers. The Genius AI Detection solution, designed to locate lesions likely to represent breast cancer, was found to perform on par with radiologists reviewing challenging breast cancer cases. Recently, Hologic announced new data from a retrospective analysis highlighting how the technology can help detect more breast cancers. The study was published in the American Journal of Roentgenology.
Between 2016 and 2019, researchers at a top-tier medical facility conducted 7,500 digital breast tomosynthesis (3D mammography) screening exams using the Genius AI Detection solution. There were 100 false-negative cases, which mammograms read as negative but were followed by a breast cancer diagnosis within the next year.
The Genius AI Detection solution marked approximately one-third (32%) of these cases, including areas of suspicion, accurately identifying the location where breast cancer was subsequently diagnosed.
Among the 500 breast cancer cases previously identified by radiologists, the Genius AI Detection technology flagged almost 90% and correctly localized their locations. The AI technology was more likely to flag invasive ductal carcinomas and lymph node-positive cancers in the study. It was less likely to flag invasive lobular carcinomas and grade I invasive carcinomas.
However, the study had limitations. Conducted at a single academic medical center with a predominantly Caucasian patient population using the Genius AI Detection 2.0 software, results may not extend to other practice settings or AI-based algorithms. The small sample sizes within certain subgroup also limit the statistical power and generalizability of the subgroup analyses.
Updates From HOLX Peers: GEHC and BDX
GE Healthcare (GEHC - Free Report) announced that it would supply more than 300 CT (computed tomography) scanners under Indonesia’s Strengthening Indonesia’s Health Referral Network (SIHREN) program to deliver equitable, high-quality care to more than 280 million Indonesians. As part of a competitively awarded, multi-year contract, the company will supply the advanced CT scanners to public hospitals across all 38 provinces, including urban and remote areas.
Becton, Dickinson and Company (BDX - Free Report) announced the expansion of its respiratory and sexually transmitted infection (STI) diagnostics offerings in Europe, with In Vitro Diagnostic Medical Device Regulation-certified VIASURE assays. BDX developed these assays in partnership with Certest Biotec for use on the BD MAX System.
HOLX Stock Performance, Valuation and Estimates
In the past three months, Hologic shares have risen 10% compared with the industry’s 8.6% growth.
Image Source: Zacks Investment Research
Hologic is trading at a forward five-year price-to-sales (P/S) of 3.86X, lower than the industry average of 4.36X.
Image Source: Zacks Investment Research
See how analysts are projecting Hologic’s fiscal 2026 and 2027 earnings.
Image Source: Zacks Investment Research
HOLX stock currently carries a Zacks Rank #3 (Hold).You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.